Showing 15 posts of 275 posts found.


Gilead struck anti-competitive deals to retain dominance in HIV market, lawsuit says

May 15, 2019
Research and Development AIDS, BMS, Gilead, HIV, Janssen, generic drugs

Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for …

Clinical trial will test long acting HIV injection

May 10, 2019
Medical Communications Art, CAB, HIV, Janssen, RPV, ViiV, injectable

A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV. The …


Janssen’s Invokana combo smashes primary and secondary endpoints in chronic kidney disease

April 16, 2019
Manufacturing and Production, Research and Development Janssen, cardiovascular, chronic kidney disease, diabetes, invokana, pharma

Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …


Janssen’s Balversa becomes first FDA-approved FGFR kinase inhibitor for advanced bladder cancer

April 15, 2019
Sales and Marketing Balversa, Cancer, FDA, Janssen, bladder cancer, pharma

Janssen’s Balversa (erdafitinib) has become the first FDA-approved fibroblast growth factor receptor (FGFR) kinase inhibitor after the US agency authorised …


Janssen’s Symtuza around 90% effective in achieving undetectable HIV-1 viral loads, when used immediately following diagnosis

April 12, 2019
Medical Communications HIV, Janssen, Symtuza, pharma

Janssen has lifted the curtain on data from the first Phase 3 trial investigating the efficacy of Symtuza (darunavir 800mg, …


Janssen closes plant in California, 49 positions axed

April 3, 2019
Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, Vacaville, california

Janssen are letting go of 49 employees due to the closure of their plant in Vacaville, California. The Johnson & …


NICE recommends Janssen’s Darzalex myeloma combo

March 12, 2019
Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma

Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within …


Janssen’s party drug-based nasal spray becomes first new FDA-approved depression treatment in 30 years

March 6, 2019
Research and Development, Sales and Marketing Janssen, Spravato, depression, esketamine, pharma

The field of depression therapy has seen its biggest leap forward in over three decades, the FDA approval of Janssen’s …


Novartis’ Cosentyx tops Janssen’s Stelara in moderate-to-severe psoriasis trial

March 5, 2019
Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma, psoriasis

New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the …


Janssen’s esketamine drug recommended by FDA panel for depression

February 13, 2019
Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma

In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …


Janssen seals global inherited retinal disease partnership with gene therapy firm MeiraGTx

February 1, 2019
Medical Communications, Research and Development, Sales and Marketing Janssen, MeiraGTx, eye care, gene therapy, pharma

In a bid to boost its portfolio in the eye care space, Janssen has announced a global partnership with clinical-stage …


Janssen’s Erleada meets primary endpoints in ongoing trial into metastatic castration-sensitive prostate cancer

January 31, 2019
Research and Development Cancer, Erleada, Janssen, pharma, prostate cancer

Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been …

Imbruvica combo scores expanded FDA approval in most common adult form of leukaemia

January 29, 2019
Manufacturing and Production, Sales and Marketing AbbVie, Cancer, Janssen, imbruvica, leukaemia, pharma

It’s big news for Janssen and AbbVie as it emerged that their jointly-developed Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) …


Darzalex “significantly reduces” disease progression and death in multiple myeloma at ASH 2018

December 5, 2018
Research and Development ASH 2018, Janssen, darzalex, multiple myeloma, pharma

Janssen has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to unveil new Phase 3 …


Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis

October 22, 2018
Research and Development, Sales and Marketing Janssen, Tremfya, pharma, plaque psoriasis, psoriasis

Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin …

Latest content